VITA 34 AG (V3V) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.078x

Based on the latest financial reports, VITA 34 AG (V3V) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€425.00K ≈ $496.87K USD) by net assets (€5.42 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of VITA 34 AG to measure how much of total assets are equity-financed.

VITA 34 AG - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how VITA 34 AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VITA 34 AG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

VITA 34 AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of VITA 34 AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ni Steel
KO:008260
0.075x
Durect Corporation
NASDAQ:DRRX
-0.447x
Youngbo Chem
KO:014440
0.027x
JAKS Resources Bhd
KLSE:4723
-0.007x
DocGo Inc
NASDAQ:DCGO
-41882.840x
Fortune Oriental Co Ltd
TW:2491
0.034x
iLearningEngines, Inc.
NASDAQ:AILE
-3.216x
Hwang-Kum Stee
KO:032560
0.014x

Annual Cash Flow Conversion Efficiency for VITA 34 AG (2006–2025)

The table below shows the annual cash flow conversion efficiency of VITA 34 AG from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see VITA 34 AG (V3V) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €5.42 Million
≈ $6.33 Million
€3.88 Million
≈ $4.53 Million
0.716x +6.75%
2024-12-31 €12.91 Million
≈ $15.09 Million
€8.65 Million
≈ $10.12 Million
0.671x +66.85%
2023-12-31 €22.77 Million
≈ $26.63 Million
€9.15 Million
≈ $10.70 Million
0.402x +242.02%
2022-12-31 €15.85 Million
≈ $18.53 Million
€-4.49 Million
≈ $-5.24 Million
-0.283x -535.27%
2021-12-31 €41.94 Million
≈ $49.03 Million
€2.73 Million
≈ $3.19 Million
0.065x -51.75%
2020-12-31 €29.54 Million
≈ $34.53 Million
€3.98 Million
≈ $4.65 Million
0.135x -35.44%
2019-12-31 €30.27 Million
≈ $35.39 Million
€6.32 Million
≈ $7.39 Million
0.209x +34.13%
2018-12-31 €29.55 Million
≈ $34.54 Million
€4.60 Million
≈ $5.38 Million
0.156x +201.50%
2017-12-31 €29.64 Million
≈ $34.66 Million
€1.53 Million
≈ $1.79 Million
0.052x -46.63%
2016-12-31 €23.65 Million
≈ $27.65 Million
€2.29 Million
≈ $2.67 Million
0.097x -11.30%
2015-12-31 €23.76 Million
≈ $27.77 Million
€2.59 Million
≈ $3.03 Million
0.109x +129.00%
2014-12-31 €22.16 Million
≈ $25.91 Million
€1.05 Million
≈ $1.23 Million
0.048x -42.89%
2013-12-31 €21.29 Million
≈ $24.89 Million
€1.77 Million
≈ $2.08 Million
0.083x -16.21%
2012-12-31 €20.49 Million
≈ $23.96 Million
€2.04 Million
≈ $2.38 Million
0.099x +391.47%
2011-12-31 €20.01 Million
≈ $23.39 Million
€-683.00K
≈ $-798.50K
-0.034x -163.72%
2010-12-31 €18.82 Million
≈ $22.00 Million
€1.01 Million
≈ $1.18 Million
0.054x -12.02%
2009-12-31 €18.87 Million
≈ $22.06 Million
€1.15 Million
≈ $1.34 Million
0.061x +137.50%
2008-12-31 €18.11 Million
≈ $21.17 Million
€-2.94 Million
≈ $-3.44 Million
-0.162x -92.47%
2007-12-31 €19.73 Million
≈ $23.07 Million
€-1.66 Million
≈ $-1.95 Million
-0.084x -219.93%
2006-12-31 €12.94 Million
≈ $15.12 Million
€-341.00K
≈ $-398.66K
-0.026x --

About VITA 34 AG

XETRA:V3V Germany Medical Care Facilities
Market Cap
$59.30 Million
€50.73 Million EUR
Market Cap Rank
#21189 Global
#1912 in Germany
Share Price
€2.91
Change (1 day)
+2.11%
52-Week Range
€2.82 - €7.45
All Time High
€17.30
About

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more